Want to see CBLL full AI Analyst Report?
CBLL Stock Chart & Stats
$16.91
$1.22(7.21%)
At close: 4:00 PM EDT
$16.91
$1.22(7.21%)
Day’s Range― - ―
52-Week Range$10.85 - $25.33
Previous Close$18.13
Volume442.39K
Average Volume (3M)265.67K
Market Cap
$928.75M
Enterprise Value$632.37
Total Cash (Recent Filing)$129.26M
Total Debt (Recent Filing)$21.91M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding38,378,100
10 Day Avg. Volume244,220
30 Day Avg. Volume265,666
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.33Price Target Upside67.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.97
Revenue Forecast (FY)$115.54M
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Recurring Subscription GrowthGrowth across both product and subscription revenue indicates expanding hospital adoption and increasing utilization. The recurring component can improve revenue visibility and support account expansion as more departments use the platform.
High Gross Margins Supported By Product ImprovementsSustained high-80s gross margins suggest attractive unit economics and provide operating leverage potential as revenue scales. Manufacturing optimization and cost initiatives may help preserve profitability per system and subscription.
Expanding Clinical Utility And Reimbursement SupportRegulatory clearances expand Ceribell’s addressable use cases beyond its core seizure application. Favorable reimbursement can strengthen hospital economics, accelerate adoption, and support future growth from delirium and other monitoring workflows.
Bears Say
Persistent Losses And Substantial Cash BurnThe company has not yet converted strong gross margins and revenue growth into positive operating earnings or cash generation. Continued losses may require financing or cash reserves, limiting flexibility if breakeven is delayed.
Operating Expenses Are Rising Faster Than RevenueExpense growth is absorbing much of the benefit from expanding revenue and delaying operating leverage. Although some litigation costs may decline, continued investment and elevated compensation create uncertainty around the path to sustainable profitability.
Adoption And New-product Revenue Timing Remain UncertainThe low penetration rate shows substantial opportunity but also highlights the challenge of converting clinical interest into scaled hospital adoption. Delayed contribution from newer products leaves future growth dependent on execution and commercialization.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $25.33 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $928.75M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 86 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.471 by -$0.039.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 38,378,100 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.471. Following the earnings report the stock price went up 10.415%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.33 (67.55% Upside)
$28.33 (67.55% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 75%
Sector Average 57%
Sector Average 57%
Hedge Fund Trend
Increased
By 89.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.91%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
CBLL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showcased strong top-line growth, high gross margins, meaningful regulatory clearances, expanding product portfolio (neonate/pediatric/delirium), and favorable reimbursement (NTAP), supported by a solid cash position and improved guidance — all material positive developments. Offsetting these positives are widening GAAP losses, materially higher operating expenses (including stock-based comp and litigation costs), continued negative adjusted EBITDA, and timing uncertainty for revenue contributions from new product initiatives. On balance, the company appears to be executing commercial and technical milestones that should drive future growth, while actively reinvesting and accepting near-term profitability pressure.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$28.33
▲(67.55% Upside)
Technical Analysis
Ownership Overview
26.13% Insiders
25.65% Mutual Funds
31.86% Other Institutional Investors
8.77% Public Companies and
Individual Investors